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Abstract
Baseline cytogenetic studies at diagnosis remain the single most important determinant of outcome in patients with acute
myeloid leukemia (AML). However, the prognostic role of the complete gamut of cytogenetic aberrations in AML patients
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently undeﬁned. In addition, their
signiﬁcance in conjunction with FLT3-ITD status has not been addressed thus far. Using the ALWP/EBMT registry we
conducted a retrospective analysis to determine the clinical outcomes of AML patients undergoing allo-HSCT with respect
to speciﬁc recurring cytogenetic abnormalities complemented with FLT3-ITD status. We analyzed a cohort consisting of
8558 adult AML patients who underwent allo-HSCT from either a matched sibling or a matched unrelated donor. Patients
with inv(3)(q21q26)/t(3;3)(q21;q26), del(5q), monosomy 7, chromosome 17p abnormalities, t(10;11)(p11-14;q13-23),
t(6;11)(q27;q23), as well as those patients with a monosomal or complex karyotype experienced signiﬁcantly inferior
leukemia-free survival (LFS) compared to patients with a normal karyotype. Trisomy 14, del(9q), and loss of chromosome X
were associated with improved LFS rates. A novel prognostic model delineating 5 distinct groups incorporating cytogenetic
complexity and FLT3-ITD status was constructed with signiﬁcant prognostic implications. Our analysis supports the added
prognostic signiﬁcance of FLT3-ITD to baseline cytogenetics in patients undergoing allo-HSCT.
Introduction
In recent years the ﬁeld of leukemia has witnessed a
remarkable incremental gain in our knowledge of the
intricate molecular underpinnings of acute myeloid leuke-
mia (AML) which has allowed for a deeper understanding
of the biology and disease process of AML [1–6].
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Notwithstanding these remarkable scientiﬁc breakthroughs,
the time-honored evaluation of cytogenetics at initial diag-
nosis still retains a crucial role in current practice and serves
as the benchmark for predicting outcome and dictating the
choice of post-remission therapy in AML patients as
reﬂected in the recently published European LeukemiaNet
(ELN) recommendations [7, 8]. Indeed, a fundamental
premise of the risk stratiﬁcation schemes employed in the
past two decades has been that patients with speciﬁcally
designated higher risk recurring cytogenetic abnormalities,
namely those patients harboring a complex [9, 10] or
monosomal [11–13] karyotype for example, are referred to
transplant at ﬁrst remission. Conversely, patients with better
prognosis karyotypic lesions such as core binding factor
(CBF), are typically consolidated with chemotherapy [14,
15]. Whereas the prognostic signiﬁcance of these com-
monly occurring cytogenetic aberrations is clearly estab-
lished, the clinical impact of the full gamut of less
commonly recurring chromosomal changes was uncovered
by the extensive analyses undertaken by the United King-
dom Medical Research Council (UKMRC) which diligently
delineated the speciﬁc prognoses effected by the full spec-
trum of cytogenetic aberrations seen in AML [16]. Fur-
thermore, the UKMRC investigators showed that increasing
level of cytogenetic complexity was a robust predictor for
worse overall outcome. However, the prognostic role this
model assumes in the prognostication of AML patients
undergoing allogeneic hematopoietic stem cell transplanta-
tion (allo-HSCT) has not been deﬁned thus far. To address
this question we paired cytogenetic analysis with compre-
hensive medical annotation using the large, registry-based
cohort of the Acute Leukemia Working Party (ALWP) of
the European Society for Blood and Marrow Transplanta-
tion (EBMT) multicenter research group. Disease and
transplant-related outcomes of the patients were analyzed
according to the speciﬁc cytogenetic aberration and degree
of karyotype complexity coupled with molecular data which
was available for a subset of patients.
Methods
Data source
Patient data were obtained from the EBMT multicenter
registry. The EBMT is an international research collabora-
tive group comprising over 650 transplant centers that
contribute detailed data on consecutive allo-HSCTs to a
statistical center at the EBMT study ofﬁce at the Saint
Antoine Hospital (Paris, France). Transplant centers in the
EBMT submit patient outcomes data for transplants to the
EBMT and undergo annual audits to ensure the integrity,
quality, and completeness of the data. The study was
approved by the ALWP review board and was performed in
compliance with the Helsinki declaration and under gui-
dance of the EBMT Institutional Review Board. All patients
provided written informed consent authorizing the use of
information for research purposes.
Study population
For this study, we selected adult AML patients undergoing
a ﬁrst allo-HSCT performed in ﬁrst remission (CR1) and
reported to the EBMT between 2006 and 2016. Our ﬁnal
study population consisted of 8558 patients transplanted
from matched related donors and HLA matched unrelated
donors with full karyotype available. Patients with t(15;17)
(q24;q21) were excluded from the analysis. Data were
contributed by 288 EBMT transplant centers. Karyotype
analysis and assessment of FLT3-ITD status were per-
formed at the time of initial AML diagnosis and were
obtained from local labs at the treating medical center.
Working deﬁnitions for chromosomal aberrations
Chromosomal abnormalities at diagnosis were assessed
according to contemporary standard nomenclature (ISCN
2009, ISCN 2013, Shaffe, Karger publishing). To deﬁne the
degree of cytogenetic complexity, we followed the metho-
dology used previously by Grimwade et al. [16] whereby
balanced translocations, chromosomal monosomies, and
chromosomal trisomies were deﬁned as a single abnorm-
ality. The gain of 2 chromosomes, unbalanced transloca-
tions, and the gain of a derivative chromosome were
counted as two abnormalities. A monosomal karyotype was
deﬁned as by the presence of at least two autosomal
monosomies or of one monosomy plus one or more struc-
tural aberrations (not including loss of a chromosome) [11].
A complex karyotype was deﬁned by the presence of more
than or equal to 4 chromosomal aberrations [17]. We only
included cytogenetic aberrancies present in at least 20
patients.
Statistical analysis
The primary endpoint used for variable selection in this
study was leukemia-free survival (LFS) which was deﬁned
as survival from the time of transplantation without evi-
dence of disease relapse or progression. Secondary end-
points were relapse incidence (RI), non-relapse mortality
(NRM), overall survival (OS), acute graft-versus-host dis-
ease (aGVHD) and chronic graft-versus-host-disease
(cGVHD), GVHD-free/relapse-free survival (GRFS).
Relapse was deﬁned as the presence of 5% BM blasts and/
or extramedullary disease. NRM was deﬁned as death
without evidence of relapse or progression. OS was deﬁned
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as the time from allo-HSCT to death, regardless of the
cause. GRFS was deﬁned as events including grade 3–4
acute GVHD, extensive chronic GVHD, relapse, or death in
the ﬁrst post-HCT year. Cumulative incidence was used to
estimate the endpoints of NRM, RI, acute and chronic to
accommodate for competing risks. To study acute and
chronic GVHD, we considered relapse and death to be
competing events. Probabilities of OS, LFS, and GRFS
were calculated using the Kaplan–Meier method. Univariate
analyses were done using Gray’s test for cumulative inci-
dence functions and the log-rank test for LFS, OS, and
GRFS.
Multivariate analyses were performed using Cox pro-
portional hazards regression for LFS. Stepwise selection
methodology (backward and forward) was used for the
selection of cytogenetics abnormalities (p ≤ 0.05) adjusted
for all other well-known prognostic variables including
patient age at transplant, gender, secondary disease, donor
type, stem cell source (bone marrow versus peripheral
blood), donor/patient cytomegalovirus matching, con-
ditioning intensity, time from diagnosis to HSCT, gender
matching (female to male vs other), and in vivo T-cell
depletion.
Subsequently, we calculated LFS according to each
selected cytogenetic abnormality and their association, and
we were able to identify four risk groups according to
favorable and adverse cytogenetic abnormalities sig-
niﬁcantly associated with LFS. Finally, we investigated the
impact of fms-like tyrosine kinase 3-internal tandem
duplication (FLT3-ITD) in the intermediate cytogenetic risk
group and a prognostic model integrating cytogenetic
aberrancy and FLT3-ITD status was constructed thereby
identifying 5 distinct prognostic groups shown in the ﬁnal
EBMT classiﬁcation. The performance of this classiﬁcation
was compared to the MRC classiﬁcation in terms of Harrell
C index using a non-parametric method developed by Kang
et al. [18]. All tests were two-sided with the type I error rate
ﬁxed at 0.05 for the determination of factors associated with
time-to-event outcomes. Statistical analyses were performed
using the SPSS 24.0 (SPSS Inc, Chicago, IL, USA) and R
3.4.1 (R Core Team (2017). R: A language and environment
for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. URL https://www.R-project.
org/)) software packages.
Results
The spectrum of cytogenetic aberrancies seen in
transplanted AML patients
Our ﬁnal cohort consisted of 8558 adult patients with a
median age of 52 years (range 18–77) who had received
Table 1 Distribution of chromosomal abnormalities in the analyzed
cohort
Chromosome Abnormality n (%)
Normal karyotype 4530 (52.9)
1 Abnormality of 1p 39 (0.46)
t(1;22)(p13;q13) 3 (0.04)
Abnormality of 1q 30 (0.35)
Trisomy 1 23 (0.27)
3 Monosomy 3 62 (0.72)
inv(3)(q21q26)/t(3;3)(q21;
q26)
151 (1.76)
t(3;5)(q21-25;q31-35) 28 (0.33)
Other abnormality of 3q 54 (0.63)
Trisomy 3 27 (0.32)
4 Trisomy 4 110 (1.29)
Monosomy 4 73 (0.85)
5 Monosomy 5 128 (1.5)
del(5q) 384 (4.49)
add(5q) 6 (0.1)
Trisomy 5 26 (0.3)
6 Trisomy 6 62 (0.72)
t(6;9)(p23;q34) 84 (0.98)
Abnormality of 6q, not t
(6;11)
32 (0.37)
Monosomy 6 46 (0.54)
7 Monosomy 7 449 (5.25)
del(7q) 281 (3.28)
add(7q) 29 (0.34)
8 Trisomy 8 751 (8.78)
t(8;21)(q22;q22) and
variants
329 (3.84)
Abnormality of 8p11-12 18 (0.21)
Monosomy 8 29 (0.34)
9 Monosomy 9 47 (0.55)
t(9;22)(q34;q11) and
variants
60 (0.7)
Deletion of 9q, including
add(9q)
119 (1.39)
Trisomy 9 44 (0.51)
10 Monosomy 10 29 (0.34)
Trisomy 10 60 (0.7)
11 Trisomy 11 121 (1.41)
t(9;11)(p21-22;q23) 223 (2.61)
t(10;11)(p11-14;q13-23) 77 (0.9)
t(6;11)(q27;q23) 81 (0.95)
t(11;19)(q23;p13) 93 (1.09)
t(11;17) 19 (0.22)
Other 11q23 324 (3.79)
Abnormality of 11q (not
11q23)
17 (0.19)
Abnormality of 11p13-15 17 (0.19)
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their ﬁrst allo-HSCT between 2006 and 2016. Baseline
clinical and demographic data are shown in Supplementary
Table 1. In all, 4530 patients (52.6%) had a normal baseline
karyotype. The most frequent abnormalities seen were
trisomy 8 (8.8%), monosomy 7 (5.2%), and chromosome 5q
abnormalities (4.6%). The complete range of the speciﬁc
cytogenetic abnormalities of patients in this analysis is
outlined in Table 1. A monosomal karyotype was seen in
533 patients (6.2%) whereas 507 patients (5.9%) were
diagnosed with a complex karyotype. Of note, of the 76
patients with loss of chromosome X, 16 were male patients
and 60 were female patients, and an association with t(8;21)
was seen in 20 of these patients (3 males and 17 females).
Supplementary Table 2 outlines the degree of chromosomal
complexity seen for each given cytogenetic aberrancy.
Association of speciﬁc cytogenetic aberrancies and
post-transplant outcomes
Next, a multivariate analysis was performed to evaluate the
impact of speciﬁc karyotypic abnormalities on the rate of
LFS. As shown in Table 2, a wide array of cytogenetic
abnormalities were associated with adverse outcome with
the notable exception of del(9q), trisomy 14, and loss of
chromosome X, all of which were signiﬁcantly associated
with better LFS rates. The 2-year outcomes of patients with
speciﬁc cytogenetic aberrancies are outlined in Supple-
mentary Table 3. We then evaluated whether increasing
cytogenetic complexity impacted signiﬁcantly on disease
and transplant-related outcomes. The analysis outlined in
Supplementary Table 4, revealed that an increasing number
of cytogenetic abnormalities was tightly correlated with
inferior rates of relapse incidence, leukemia-free survival,
and overall survival. Additionally, patients with monosomal
or complex karyotypes also experienced signiﬁcantly worse
disease related outcomes. Of note, patients with inv(16)
(p13q22)/t(16;16)(p13;q22), experienced favorable LFS
irrespective of the number of concomitant chromosomal
abnormalities.
Classiﬁcation of cytogenetic risk groups in
transplanted patients
The initial classiﬁcation of patients into speciﬁc prognostic
groups was initially carried out by allocating patients into
four prognostic groups based on a hazard ratio of less or
more than 1 after stepwise selection of the rate of LFS.
Patients were thus classiﬁed either as favorable risk or poor
risk, respectively, while patients with a karyotype consisting
of both complex cytogenetics and a monosomal karyotype
were classiﬁed as very poor (Fig. 1). Thus, the favorable
risk group consisted of patients with the following cytoge-
netic features: deletion of 9q, including add(9q) irrespective
of additional cytogenetic abnormalities, trisomy 14 in the
absence of a complex karyotype, inv(16)(p13q22)/t(16;16)
(p13;q22) irrespective of additional cytogenetic
Table 1 (continued)
Chromosome Abnormality n (%)
Monosomy 11 33 (0.39)
12 Monosomy 12 41 (0.48)
Other abnormality of 12p13 27 (0.32)
Other abnormality of 12p,
not 12p13
51 (0.6)
13 Trisomy 13 225 (2.63)
Monosomy 13 55 (0.64)
Deletion of 13q 57 (0.67)
14 Trisomy 14 53 (0.62)
15 Abnormality of 15q, not t
(15;17)
15 (0.16)
Monosomy 15 39 (0.46)
Trisomy 15 21 (0.25)
16 inv(16)(p13q22)/t(16;16)
(p13;q22)
277 (3.24)
Abnormality of 16q, not inv
(16)
25 (0.29)
Monosomy 16 61 (0.71)
Trisomy 16 19 (0.22)
17 Monosomy 17 125 (1.46)
Abnormality of 17p 93 (1.09)
18 Monosomy 18 92 (1.08)
Trisomy 18 27 (0.32)
19 Trisomy 19 71 (0.83)
Monosomy 19 30 (0.35)
20 Monosomy 20 70 (0.82)
Abnormality of 20q 57 (0.67)
Trisomy 20 32 (0.37)
21 Trisomy 21 (acquired) 167 (1.95)
Abnormality of 21q, not
t(8;21)
24 (0.28)
Monosomy 21 62 (0.72)
22 Trisomy 22 79 (0.92)
Monosomy 22 28 (0.33)
X Loss of X 76 (0.89)
Y Loss of Y 117 (1.37)
Other abnormalities 247 (2.89)
Degree of karyotype
complexity
n (%)
Normal karyotype 4530 (52.59)
1 abnormality 2314 (27.04)
2 abnormalities 745 (8.7)
3 abnormalities 462 (5.4)
4 abnormalities 200 (2.24)
5 or more abnormalities 307 (3.59)
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abnormalities, and patients with loss of chromosome X in
the absence of a complex karyotype. Patients in the poor
risk group were those with the following high risk features:
inv(3)(q21q26)/t(3;3)(q21;q26), del(5q), monosomy 7,
t(10;11)(p11-14;q13-23), t(6;11)(q27;q23), abnormality of
17p, trisomy 19, and the presence of either a monosomal or
complex karyotype.
Patients classiﬁed as favorable risk experienced 2 year RI
and LFS rates of 17.8 and 72.2%, respectively, sharply
contrasting with the very poor outcomes seen in patients
with both complex cytogenetics and a monosomal kar-
yotype where the 2 year RI and LFS rates were 66.5 and
18.9%, respectively. The outcome of patients according to
the MRC classiﬁcation and the EBMT classiﬁcation are
outlined in Supplementary Figure 1. Harrell’s C index was
used to measure how well the prognostic model dis-
criminated patients with or without the event of interest.
The calculated C-indexes were 0.576 [95% CI: 0.564–
0.588] and 0.609 [95% CI: 0.597–0.621] for the MRC and
the EBMT classiﬁcations, respectively. In Supplementary
Table 5, a comparison between speciﬁc cytogenetic
abnormalities and their respective risk designation in the
MRC and our classiﬁcation is provided.
Incorporation of FLT3-ITD mutation status into the
prognostic model
Since FLT3-ITD is a pivotal determinant of patient outcome
in AML, an additional classiﬁcation model including FLT3-
ITD mutational status was evaluated for the subset of
patients with available molecular data (n= 2473). In all,
51% of evaluable patients were FLT3-ITD mutated and as
shown in Supplementary Table 2, patients with trisomy 4,
t(6;9)(p23;q34), and t(8;21)(q22;q22) were with the highest
rate of FLT3-ITD positivity. In this model, ﬁve distinct
groups in terms of prognosis could be identiﬁed (Table 3,
Fig. 2). Notably, we found that the presence of FLT3-ITD
was signiﬁcantly associated with outcome only in the
intermediate cytogenetic risk group, thus in the expanded 5
group model, we were able to include also the patients from
the favorable risk, high risk and very high-risk groups in the
expanded classiﬁcation, resulting in a total number of 5115
patients. The best outcome with regard to RI, LFS, and OS
was seen for those patients with either favorable risk cyto-
genetic abnormalities (n= 489) or intermediate risk cyto-
genetics and not FLT3-ITD mutated (n= 1749) (2-year LFS
rates of 72 and 66%, respectively). Patients mutated for
FLT3-ITD with an intermediate-risk karyotype (n= 1476)
had poorer outcomes compared to patients with inter-
mediate risk cytogenetics and not harboring the FLT3-ITD
mutation (2-year LFS rate of 57%). Finally, patients with
poor-risk cytogenetics (n= 1116) experienced signiﬁcantly
worse outcomes (2 year LFS rate of 41%) whereas the least
favorable outcomes were seen in the group of patients (n=
285) with the composite of a monosomal and complex
karyotype (2 year LFS rate of 19%).
Table 2 Impact of cytogenetic
abnormalities on leukemia-free
survival after stepwise selection
Chromosome Abnormality HR 95% CI p
Normal karyotype
3 inv(3)(q21q26)/t(3;3)(q21;q26) 1.76 1.42–2.18 < 0.001
5 del(5q) 1.36 1.17–1.57 < 0.001
7 Monosomy 7 1.31 1.14–1.5 < 0.001
14 Trisomy 14 0.59 0.36–0.97 0.04
9 del(9q) 0.59 0.41–0.85 0.004
10 t(10;11)(p11-14;q13-23) 1.49 1.1–2.01 0.01
11 t(6;11)(q27;q23) 1.54 1.15–2.08 0.004
17 Abnormality of 17p 1.42 1.09–1.86 0.01
19 Trisomy 19 1.53 1.11–2.11 0.01
X Loss of X 0.54 0.36–0.8 0.002
Complex karyotype 1.37 1.18–1.6 < 0.001
Monosomal karyotype 1.59 1.37–1.85 < 0.001
Fig. 1 Leukemia-free survival of transplanted AML patients according
to EBMT cytogenetic classiﬁcation
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Discussion
Notwithstanding the incorporation of novel innovative
molecular risk stratiﬁcation models into modern prog-
nostication schemas of AML patients [8, 19, 20], baseline
cytogenetic studies still serve as an invaluable prognostic
tool for prediction of outcome at key clinical time points
during the therapeutic sequence of AML patients [7].
Indeed, cytogenetic abnormalities have been previously
established as robust predictors of the risk of primary
induction resistance [21], risk of relapse [22, 23], and out-
come following transplant for primary refractory disease
[24]. Yet, to what extent these chromosomal abnormalities
impact on patients undergoing allo-HSCT has not been fully
addressed hitherto. Herein, we outline the speciﬁc clinical
outcomes experienced for the full range of the cytogenetic
spectrum, and we establish a novel prognostic model
incorporating speciﬁc cytogenetic aberrations with cytoge-
netic complexity and FLT3-ITD status.
While in general, our results were consistent with what
Grimwade et al. had previously published with the MRC
analysis there were several notable differences. Unlike the
MRC publication, our analysis indicates that t(3;5),
t(11;19), and t(9;22) were not signiﬁcant in terms of LFS.
There are several possible explanations to the different
outcome experienced by these patient segments which ﬁrst
and foremost most likely result from the fact that our ana-
lysis consisted only of patients which underwent transplant
whereas the MRC data analyzed all comers. Furthermore,
patients with t(11;19) were more signiﬁcantly represented in
our cohort compared to the MRC analysis; 93 patients with t
(11;19) in our registry compared to 30 in the MRC dataset.
It is also worth noting that while t(11;19) is an established
poor prognostic factor [25, 26], data from the MD Anderson
Cancer Center suggests that transplantation had a signiﬁcant
beneﬁt for this patient segment resulting in superior overallTa
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Fig. 2 Leukemia-free survival of transplanted AML patients using the
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survival and relapse-free survival [27]. It is not completely
clear to us why patients with t(9;22) and t(3;5), two
uncommon cytogenetic presentations of AML [28], did
better in our analysis, however it may be possible that
transplantation or the increased use of tyrosine kinase
inhibitors improved the suboptimal prognosis of these
patients. Additionally, we note that a smaller study of 7
patients with t(3;5) suggested these patients had inter-
mediate prognosis [29]. Interestingly and diverging from
the MRC data, our ﬁndings reveal that trisomy of chro-
mosome 19 is associated with worse outcomes. Isolated
trisomy 19 is a rare abnormality that has been reported
previously with some cases evolving from antecedent
myelodysplasia with no clear prognostic inﬂuence [30].
Conversely, in our analysis loss of chromosome X, chro-
mosome 9q deletion and trisomy 14 were found to be
correlated with signiﬁcantly improved clinical outcome in
our patient cohort. Deletion of the long arm of chromosome
9 can present as an isolated abnormality with no measurable
impact prognosis [31] or in combination with other cyto-
genetic aberrations such as t(8;21) where according to data
from the French CBF-AML intergroup it does negatively
impact on overall survival and leukemia-free survival [32].
Loss of chromosome X is a frequent ﬁnding in patients with
t(8;21) [33] but has not been found to impact on patient
outcome in AML. Trisomy 14 was not seen in the MRC
analysis and was diagnosed in 53 patients in our cohort, this
rare chromosomal abnormality has been reported to occur
mostly in elderly male AML patients with a signiﬁcant
component of dysplasia [34]. In accordance with previous
literature, we found that outcomes for CBF patients
diverged whereby patients with inv(16)(p13q22) experi-
enced superior outcomes compared to patients with t(8;21)
(q22;q22). Notably, similar observations were made pre-
viously by the Japan Society for Hematopoietic Cell
Transplantation group [35], The German-Austrian AML
Study Group [6], and more recently by Halaburda and
colleagues from the EBMT in CBF patients undergoing
transplant in CR2 [36]. Finally, whereas in the 2017 ELN
classiﬁcation t(6;9)(p23;q34.1) is considered an adverse
prognostic cytogenetic lesion, our data, supported by the
MRC analysis as well as by transplant data from Japan [37],
indicate that t(6;9)(p23;q34.1) is prognostically associated
with intermediate-risk disease.
As molecular data was available only in a small patient
subset of the MRC cohort (n= 215), an additional aim of
our analysis was to incorporate FLT3-ITD into our working
model to further stratify patient outcome in the intermediate
cytogenetic risk group. Our ﬁnal model which was per-
formed on over 2400 AML patients with available FLT3-
ITD data did delineate quite different outcomes for trans-
planted patients in terms of LFS and RI. Indeed, FLT3-ITD
patients experienced a 2-year relapse rate of nearly 30%
compared with 19% of patient with FLT3-WT. Thus, and
not surprisingly, FLT3-ITD adds an additional important
prognostic facet to cytogenetics in the prediction of clinical
outcome of transplanted AML patients which is consistent
with previous publications in the ﬁeld [38–40].
An extensive body of literature published over the past
two decades ﬁrmly demonstrates that AML patients with
either a monosomal karyotype or a complex karyotype
experience signiﬁcantly worse outcomes compared to
patients absent of these cytogenetic features. Furthermore,
Haferlach and colleagues suggest that the combination of a
monosomal karyotype and complex cytogenetics confers
even worse prognosis [41]. Our analysis reafﬁrms the poor
prognosis seen in monosomal karyotype patients previously
published by the Center for International Blood and Marrow
Transplant Research (CIBMTR) [42] and others [12, 43–
46]. Our data clearly show that an increasing degree of
cytogenetic complexity directly translates into an increased
risk of relapse and signiﬁcantly worse leukemia-free sur-
vival and overall survival. Indeed, patients with a single
karyotypic abnormality had a 2-year relapse rate of 28%
compared to the rate of 56% seen in patients with 5 or more
chromosomal abnormalities. These ﬁndings are in line with
the MRC experience as well as with those of the Study
Alliance Leukemia who also found that patients with 4 or
more cytogenetic abnormalities to have worse prognosis
compared to those with only 3 cytogenetic abnormalities
[17]. Notably, in an analysis of over 1500 patients enrolled
on the ECOG-ACRIN trials, having a monosomal kar-
yotype had no incremental impact on survival of patients
harboring a complex karyotype of 5 or more chromosomal
abnormalities, thus leading the authors of the study to
suggest that the prognostic impact of a monosomal kar-
yotype being limited to patients with less complex kar-
yotypes [47]. Our data also concur with a CIBMTR analysis
conducted in 821 adults transplanted AML patients showing
that complex karyotype (≥ 4 abnormalities) was still an
adverse prognostic factor following transplantation [48].
There are several noteworthy limitations to our study.
First, this being a large registry study did not allow for
centralized review of cytogenetic studies which may have
provided further information such as the distinction between
KMT2A-MLLT1 (MLL-ENL) and KMT2A-ELL (MLL-ELL)
fusion genes in t(11;19)(q23;q13). In addition, further
aspects relating to cytogenetics were not captured by our
registry such as clonal heterogeneity which has been shown
previously to signiﬁcantly impact on patient outcome [49].
In conclusion, in this analysis, we deﬁne the cytogenetic
horizon of AML patients who underwent allo-HSCT during
the past decade and delineate the clinical outcome of
patients according to baseline cytogenetics studies coupled
with FLT-ITD mutational status. We believe the EBMT
score can complement the ELN 2017 recommendations for
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those patients referred to transplant (based on ELN 2017)
and further aid in prediction of post-transplant outcomes by
providing clinicians a general sense of outcomes. Further-
more, the risk of relapse as predicted by the EBMT score,
may possibly inﬂuence clinical decision-making regarding
the intensity of post-transplant maintenance strategies. This
study further underscores the notion that despite the para-
mount anti-leukemia effect exerted by allogeneic trans-
plantation, baseline cytogenetic studies retain pivotal and
lasting prognostic consequences on patient outcome.
Ongoing and future trials with FLT3 inhibitors and other
targeted agents following transplantation will hopefully
mitigate some of the detrimental consequences associated
with a baseline adverse risk karyotype and FLT3-ITD.
Acknowledgements We thank all the European Group for Blood and
Marrow Transplantation (EBMT) centers and national registries for
contributing patients to the study and data managers for their excellent
work.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interest.
Publisher’s note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.
References
1. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC,
Welch JS, et al. Clonal evolution in relapsed acute myeloid leu-
kaemia revealed by whole-genome sequencing. Nature. 2012;
481:506–10.
2. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC,
et al. The origin and evolution of mutations in acute myeloid
leukemia. Cell. 2012;150: 264–78.
3. Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L,
Raphael BJ, Mungall AJ, et al. Genomic and epigenomic land-
scapes of adult de novo acute myeloid leukemia. N Engl J Med.
2013;368:2059–74.
4. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta
V, et al. Identiﬁcation of pre-leukaemic haematopoietic stem cells
in acute leukaemia. Nature. 2014;506:328–33.
5. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen
SL, et al. Acute myeloid leukemia ontogeny is deﬁned by distinct
somatic mutations. Blood. 2015;125:1367–76.
6. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI,
Paschka P, Roberts ND, et al. Genomic Classiﬁcation and Prog-
nosis in Acute Myeloid Leukemia. N Engl J Med. 2016;
374:2209–21.
7. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation
for patients with AML in ﬁrst complete remission. Blood.
2016;127:62–70.
8. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR,
Buchner T, et al. Diagnosis and management of AML in adults:
2017 ELN recommendations from an international expert panel.
Blood. 2017;129:424–47.
9. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS,
Mohamed A, et al. Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid
leukemia: a Southwest Oncology Group/Eastern Cooperative
Oncology Group Study. Blood. 2000;96:4075–83.
10. Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier
P, et al. Relapse and survival after transplantation for complex
karyotype acute myeloid leukemia: A report from the Acute
Leukemia Working Party of the European Society for Blood and
Marrow Transplantation and the University of Texas MD
Anderson Cancer Center. Cancer. 2018;124; 2134–41.
11. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola
SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal kar-
yotype in acute myeloid leukemia: a better indicator of poor
prognosis than a complex karyotype. J Clin Oncol. 2008;26:
4791–7.
12. Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Pass-
weg JR, Pabst T, et al. Comparative analysis of the value of
allogeneic hematopoietic stem-cell transplantation in acute mye-
loid leukemia with monosomal karyotype versus other cytogenetic
risk categories. J Clin Oncol. 2012;30:2140–6.
13. Brands-Nijenhuis AV, Labopin M, Schouten HC, Volin L, Socie
G, Cornelissen JJ, et al. Monosomal karyotype as an adverse
prognostic factor in patients with acute myeloid leukemia treated
with allogeneic hematopoietic stem-cell transplantation in ﬁrst
complete remission: a retrospective survey on behalf of the ALWP
of the EBMT. Haematologica. 2016;101:248–55.
14. Kurosawa S, Miyawaki S, Yamaguchi T, Kanamori H, Sakura T,
Moriuchi Y, et al. Prognosis of patients with core binding factor
acute myeloid leukemia after ﬁrst relapse. Haematologica.
2013;98:1525–31.
15. Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun
T, et al. Core-binding factor acute myeloid leukemia in ﬁrst
relapse: a retrospective study from the French AML Intergroup.
Blood. 2014;124:1312–9.
16. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S,
Goldstone AH, et al. Reﬁnement of cytogenetic classiﬁcation in
acute myeloid leukemia: determination of prognostic signiﬁcance
of rare recurring chromosomal abnormalities among 5876 younger
adult patients treated in the United Kingdom Medical Research
Council trials. Blood. 2010;116:354–65.
17. Stolzel F, Mohr B, Kramer M, Oelschlagel U, Bochtler T, Berdel
WE, et al. Karyotype complexity and prognosis in acute myeloid
leukemia. Blood Cancer J. 2016;6:e386.
18. Kang L, Chen W, Petrick NA, Gallas BD. Comparing two cor-
related C indices with right-censored survival outcome: a one-shot
nonparametric approach. Stat Med. 2015;34:685–703.
19. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T,
Rapaport F, et al. Distinct evolution and dynamics of epigenetic
and genetic heterogeneity in acute myeloid leukemia. Nat Med.
2016;22:792–9.
20. Wang M, Lindberg J, Klevebring D, Nilsson C, Mer AS, Ranta-
lainen M, et al. Validation of risk stratiﬁcation models in acute
myeloid leukemia using sequencing-based molecular proﬁling.
Leukemia. 2017;31:2029–36.
21. Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA,
Rothenberg-Thurley M, Ksienzyk B, et al. A 29-gene and cyto-
genetic score for the prediction of resistance to induction treatment
in acute myeloid leukemia. Haematologica. 2018;103:456–65.
22. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur
DC, et al. Pretreatment cytogenetic abnormalities are predictive of
induction success, cumulative incidence of relapse, and overall
survival in adult patients with de novo acute myeloid leukemia:
results from Cancer and Leukemia Group B (CALGB 8461).
Blood. 2002;100:4325–36.
23. Hackl H, Astanina K, Wieser R. Molecular and genetic alterations
associated with therapy resistance and relapse of acute myeloid
leukemia. J Hematol Oncol. 2017;10:51.
Prognostic signiﬁcance of recurring chromosomal abnormalities in transplanted patients with acute. . . 1951
24. Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R,
Finke J, et al. Comparison of matched sibling donors versus
unrelated donors in allogeneic stem cell transplantation for pri-
mary refractory acute myeloid leukemia: a study on behalf of the
Acute Leukemia Working Party of the EBMT. J Hematol Oncol.
2017;10:130.
25. Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G,
et al. Prognostic factors in adult patients up to 60 years old with
acute myeloid leukemia and translocations of chromosome band
11q23: individual patient data-based meta-analysis of the German
Acute Myeloid Leukemia Intergroup. J Clin Oncol.
2009;27:3000–6.
26. Bhatnagar B, Blachly JS, Kohlschmidt J, Eisfeld AK, Volinia S,
Nicolet D, et al. Clinical features and gene- and microRNA-
expression patterns in adult acute leukemia patients with t(11;19)
(q23; p13.1) and t(11;19)(q23;p13.3). Leukemia. 2016;30:
1586–9.
27. Chen Y, Kantarjian H, Pierce S, Faderl S, O’Brien S, Qiao W,
et al. Prognostic signiﬁcance of 11q23 aberrations in adult acute
myeloid leukemia and the role of allogeneic stem cell transplan-
tation. Leukemia. 2013;27:836–42.
28. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau
MM, et al. The2016 revision to the World Health Organization
classiﬁcation of myeloid neoplasms and acute leukemia. Blood.
2016;127:2391–405.
29. Dumezy F, Renneville A, Mayeur-Rousse C, Nibourel O, Labis E,
Preudhomme C. Acute myeloid leukemia with translocation
t(3;5): new molecular insights. Haematologica. 2013;98:e52–4.
30. Johansson B, Billstrom R, Mauritzson N, Mitelman F. Trisomy 19
as the sole chromosomal anomaly in hematologic neoplasms.
Cancer Genet Cytogenet. 1994;74:62–5.
31. Peniket AJ. Del(9q) acute myeloid leukaemia: clinical and cyto-
logical characteristics and prognostic implications. Br J Haematol.
2005;130:969. author reply
32. Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn
JY, et al. Acute myeloid leukemia with translocation (8;21) or
inversion (16) in elderly patients treated with conventional che-
motherapy: a collaborative study of the French CBF-AML inter-
group. J Clin Oncol. 2009;27:4747–53.
33. Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D,
Haferlach T, et al. Identiﬁcation of additional cytogenetic and
molecular genetic abnormalities in acute myeloid leukaemia with t
(8;21)/AML1-ETO. Br J Haematol. 2006;134:616–9.
34. Cui W, Bueso-Ramos CE, Yin CC, Sun J, Chen S, Muddasani R,
et al. Trisomy 14 as a sole chromosome abnormality is associated
with older age, a heterogenous group of myeloid neoplasms with
dysplasia, and a wide spectrum of disease progression. J Biomed
Biotechnol. 2010;2010:365318.
35. Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A,
Ogawa H, et al. Hematopoietic stem cell transplantation for core
binding factor acute myeloid leukemia: t(8;21) and inv(16)
represent different clinical outcomes. Blood. 2009;113:2096–103.
36. The 44th Annual Meeting of the European Society for Blood and
Marrow Transplantation: Physicians Oral Session. Bone
Marrow Transplantation. 2018; https://doi.org/10.1038/s41409-
018-0318-y.
37. Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Maeda T,
et al. Allogeneic hematopoietic stem cell transplantation for acute
myeloid leukemia with t(6;9)(p23; q34) dramatically improves the
patient prognosis: a matched-pair analysis. Leukemia.
2012;26:461–4.
38. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A,
Bullinger L, et al. Mutations and treatment outcome in cytogen-
etically normal acute myeloid leukemia. N Engl J Med.
2008;358:1909–18.
39. Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori AP,
et al. Impact of FLT3 internal tandem duplication on the outcome
of related and unrelated hematopoietic transplantation for adult
acute myeloid leukemia in ﬁrst remission: a retrospective analysis.
J Clin Oncol. 2012;30:735–41.
40. Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A,
et al. Outcome of patients with distinct molecular genotypes and
cytogenetically normal AML after allogeneic transplantation.
Blood. 2015;126:2062–9.
41. Haferlach C, Alpermann T, Schnittger S, Kern W, Chromik J,
Schmid C, et al. Prognostic value of monosomal karyotype in
comparison to complex aberrant karyotype in acute myeloid leu-
kemia: a study on 824 cases with aberrant karyotype. Blood.
2012;119:2122–5.
42. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH,
Nishihori T, et al. Hematopoietic cell transplantation outcomes in
monosomal karyotype myeloid malignancies. Biol Blood Marrow
Transplant. 2016;22:248–57.
43. Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y,
Ago H, et al. Prognosis of acute myeloid leukemia harboring
monosomal karyotype in patients treated with or without allo-
geneic hematopoietic cell transplantation after achieving complete
remission. Haematologica. 2012;97:915–8.
44. Poire X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C,
Veelken JH, et al. Outcome of conditioning intensity in acute
myeloid leukemia with monosomal karyotype in patients over 45
year-old: A study from the acute leukemia working party (ALWP)
of the European group of blood and marrow transplantation
(EBMT). Am J Hematol. 2015;90:719–24.
45. Kayser S, Zucknick M, Dohner K, Krauter J, Kohne CH, Horst
HA, et al. Monosomal karyotype in adult acute myeloid leukemia:
prognostic impact and outcome after different treatment strategies.
Blood. 2012;119:551–8.
46. Fang M, Storer B, Estey E, Othus M, Zhang L, Sandmaier BM,
et al. Outcome of patients with acute myeloid leukemia with
monosomal karyotype who undergo hematopoietic cell trans-
plantation. Blood. 2011;118):1490–4.
47. Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD,
Dewald G, et al. Independent Prognostic Signiﬁcance Of
Monosomy 17 and Impact of Karyotype Complexity in Mono-
somal Karyotype/Complex Karyotype Acute Myeloid Leukemia:
Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
Leuk Res. 2017;59:55–64.
48. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp
TR, et al. Classifying cytogenetics in patients with acute myelo-
genous leukemia in complete remission undergoing allogeneic
transplantation: a Center for International Blood and Marrow
Transplant Research study. Biol Blood Marrow Transplant.
2012;18:280–8.
49. Medeiros BC, Othus M, Fang M, Appelbaum FR, Erba HP.
Cytogenetic heterogeneity negatively impacts outcomes in
patients with acute myeloid leukemia. Haematologica.
2015;100:331–5.
1952 J. Canaani et al.
